logo-loader
viewAmgen, Inc.

Amgen pleased with Phase III anemia trial results

Anemia is a condition in which there is a deficiency of red cells or of haemoglobin in the blood, resulting in tiredness and a lack of energy.

rsz_shutterstock_128572838.jpg
The trial was conducted on aenemic patients with a low to intermediate risk of myelodysplastic syndrome (MDS),

Pharma firm Amgen (NASDAQ:AMGN) confirmed that its Phase III test of Aranesp successfully reduced red blood cell transfusions in anemic patients.

The randomized, double-blind, placebo-controlled trial showed the treatment for anemia associated with chronic renal failure worked over a 25-week study period.

Aranesp also significantly improved erythroid response, a key measure of the formation of new red blood cells, the company said.

Anemia is a condition in which there is a deficiency of red cells or of haemoglobin in the blood, resulting in tiredness and a lack of energy.

The trial was conducted on anemic patients with a low to intermediate risk of myelodysplastic syndrome (MDS), a blood disorder that causes a drop in healthy blood cells.

MDS occurs when immature blood cells do not mature in the bone marrow and patients have fewer healthy white blood cells, red blood cells and platelets, increasing the risk of infection, anemia or bleeding.

Sean Harper, executive vice president of research and development at Amgen, said: “We are pleased to see positive results from this study, as anemia treatment options for myelodysplastic syndrome are limited and can place a significant burden on patients.” 

Quick facts: Amgen, Inc.

Price: 225.51 USD

NASDAQ:AMGN
Market: NASDAQ
Market Cap: $133.99 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks green across the board; Curaleaf joins fellow...

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, grew 4.6% at 114.8 points. Elsewhere, the OTCQX Cannabis gained 6% at 466.7 points. Buds today are Curaleaf Holdings Inc (CSE:CURA) (OTCMKTS:CURLF), Trulieve Cannabis Corp...

9 hours, 14 minutes ago

2 min read